Through Exquisite Control
Serious diseases can result if the immune system consistently under- or over-responds. Our first-in-class medicines precisely control immune responses in patients with inflammatory or autoimmune disorders, and enhance responses in patients with cancer.
A Leading Portfolio of
First-in-Class Small Molecules
We are working with urgency to develop novel drugs that meet the needs of patients with inflammatory disorders and cancer.
The IFM Team Has an Unprecedented Track Record
Among the team's achievements in the company's first 3.5 years has been the progression of 3 novel programs from the standing start through to the clinic and the closing of 2 major deals.
IFM founded by G. Glick and seed-financed by Atlas Venture to discover agonists of NLRP3 for cancer.
Novel and proprietary NLRP3 agonist leads identified
Novel and proprietary STING agonists discovered
IFM's $27M Series A closed
Preclinical PoC for both NLRP3 and STING agonists demonstrated
$2.32B sale of IFM Uno to BMS closed; IFM Therapeutics, LLC created as a spin-out, and IFM Tre launched
BMS dosed initial patient with first-in-class NLRP3 agonist, IFM-1222
IFM Tre's $31M Series A financing closed (focus on NLRP3 antagonist)
IFM Due launched (focus on cGAS/STING antagonists)
IFM Tre dosed initial subject with first-in-class NLRP3 antagonist, IFM-2427
BMS dosed first patient with STING agonist, IFM-1364
$1.575B sale of IFM Tre to Novartis closed
IFM Quattro and IFM Discovery launched with $55.5M financing from Omega Funds, Atlas Venture and Abingworth